The necessity of human trials of putative therapies for Alzheimer's disease

David Knopman

doi:10.1016/0197-4580(89)90158-9

The necessity of human trials of putative therapies for Alzheimer's disease

David Knopman

Neurology

Research output: Contribution to journal › Article › peer-review

Abstract

The absence of a suitable animal model for Alzheimer's disease leaves therapeutic trials in human subjects as a necessity. Reasonable criteria can be formulated for deciding which therapies should be tested. Scientific rationale and likelihood of success should be major considerations. Novel approaches of delivering drugs to the central nervous system should not be discouraged so long as complication rates can be shown to be low.

Original language	English (US)
Pages (from-to)	633-634
Number of pages	2
Journal	Neurobiology of aging
Volume	10
Issue number	5
DOIs	https://doi.org/10.1016/0197-4580(89)90158-9
State	Published - 1989

ASJC Scopus subject areas

General Neuroscience
Aging
Clinical Neurology
Developmental Biology
Geriatrics and Gerontology

Access to Document

10.1016/0197-4580(89)90158-9

Cite this

@article{0b9a54c1a7af495a8bed065d69c37e13,

title = "The necessity of human trials of putative therapies for Alzheimer's disease",

abstract = "The absence of a suitable animal model for Alzheimer's disease leaves therapeutic trials in human subjects as a necessity. Reasonable criteria can be formulated for deciding which therapies should be tested. Scientific rationale and likelihood of success should be major considerations. Novel approaches of delivering drugs to the central nervous system should not be discouraged so long as complication rates can be shown to be low.",

author = "David Knopman",

note = "Funding Information: Supported in part by Grant P50AG05134-05, NIA: the Sterling Morton Research Fund; a grant from the Commonwealth of Massachusetts, 5-29343; and the Stanley and Harriet Friedman Fund for Research in Alzheimer's Disease.",

year = "1989",

doi = "10.1016/0197-4580(89)90158-9",

language = "English (US)",

volume = "10",

pages = "633--634",

journal = "Neurobiology of aging",

issn = "0197-4580",

publisher = "Elsevier Inc.",

number = "5",

}

TY - JOUR

T1 - The necessity of human trials of putative therapies for Alzheimer's disease

AU - Knopman, David

N1 - Funding Information: Supported in part by Grant P50AG05134-05, NIA: the Sterling Morton Research Fund; a grant from the Commonwealth of Massachusetts, 5-29343; and the Stanley and Harriet Friedman Fund for Research in Alzheimer's Disease.

PY - 1989

Y1 - 1989

N2 - The absence of a suitable animal model for Alzheimer's disease leaves therapeutic trials in human subjects as a necessity. Reasonable criteria can be formulated for deciding which therapies should be tested. Scientific rationale and likelihood of success should be major considerations. Novel approaches of delivering drugs to the central nervous system should not be discouraged so long as complication rates can be shown to be low.

AB - The absence of a suitable animal model for Alzheimer's disease leaves therapeutic trials in human subjects as a necessity. Reasonable criteria can be formulated for deciding which therapies should be tested. Scientific rationale and likelihood of success should be major considerations. Novel approaches of delivering drugs to the central nervous system should not be discouraged so long as complication rates can be shown to be low.

UR - http://www.scopus.com/inward/record.url?scp=0024367319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024367319&partnerID=8YFLogxK

U2 - 10.1016/0197-4580(89)90158-9

DO - 10.1016/0197-4580(89)90158-9

M3 - Article

C2 - 2572987

AN - SCOPUS:0024367319

SN - 0197-4580

VL - 10

SP - 633

EP - 634

JO - Neurobiology of aging

JF - Neurobiology of aging

IS - 5

ER -

The necessity of human trials of putative therapies for Alzheimer's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this